Mammary Tumors Growing in the Absence of Growth Hormone Are More Sensitive to Doxorubicin Than Wild-Type Tumors
Open Access
- 1 April 2021
- journal article
- research article
- Published by The Endocrine Society in Endocrinology
- Vol. 162 (4)
- https://doi.org/10.1210/endocr/bqab013
Abstract
Previously, we reported that N-methyl-N-nitrosourea (MNU)-induced mammary tumors could be established in mutant spontaneous dwarf rats (SDRs), which lack endogenous growth hormone (GH) by supplementing with exogenous GH, and almost all such tumors regressed upon GH withdrawal. When the highly inbred SDR line was outcrossed to wild-type (WT) Sprague-Dawley rats, MNU-induced mammary tumors could still be established in resulting outbred SDRs by supplementing with exogenous GH. However, unlike tumors in inbred SDRs, 65% of mammary tumors established in outbred SDRs continued growth after GH withdrawal. We further tested whether these tumors were more sensitive to doxorubicin than their WT counterparts. To accomplish this, MNU-induced mammary tumors were established in WT rats and in SDRs supplemented with exogenous GH. Once mammary tumors reached 1 cm3 in size, exogenous GH was withdrawn from SDRs, and the subset that harbored tumors that continued or resumed growth in the absence of GH were selected for doxorubicin treatment. Doxorubicin was then administered in 6 injections over 2 weeks at 2.5 mg/kg or 1.25 mg/kg for both the WT and SDR groups. The SDR mammary tumors that had been growing in the absence of GH regressed at both doxorubicin doses while WT tumors continued to grow robustly. The regression of SDR mammary tumors treated with 1.25 mg/kg doxorubicin was accompanied by reduced proliferation and dramatically higher apoptosis relative to the WT mammary tumors treated with 1.25 mg/kg doxorubicin. These data suggest that downregulating GH signaling may decrease the doxorubicin dose necessary to effectively treat breast cancer.Keywords
Funding Information
- National Institutes of Health (R21CA238105)
- National Cancer Institute
This publication has 43 references indexed in Scilit:
- High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti–IGF-IR TherapyClinical Cancer Research, 2011
- Congenital IGF1 deficiency tends to confer protection against post-natal development of malignanciesActa Endocrinologica, 2011
- Sequencing of Type I Insulin-Like Growth Factor Receptor Inhibition Affects Chemotherapy Response In vitro and In vivoClinical Cancer Research, 2009
- Constitutively Active Type I Insulin-Like Growth Factor Receptor Causes Transformation and Xenograft Growth of Immortalized Mammary Epithelial Cells and Is Accompanied by an Epithelial-to-Mesenchymal Transition Mediated by NF-κB and SnailMolecular and Cellular Biology, 2007
- Inhibition of estrogen-independent mammary carcinogenesis by disruption of growth hormone signalingCarcinogenesis: Integrative Cancer Research, 2007
- The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growthBreast Cancer Research and Treatment, 2006
- Congestive heart failure in patients treated with doxorubicinCancer, 2003
- Temporal sequence of mammary intraductal proliferations, ductal carcinomas in situ and adenocarcinomas induced by 1-methyl-1- nitrosourea in ratsCarcinogenesis: Integrative Cancer Research, 1998
- Rapid induction of mammary intraductal proliferations, ductal carcinoma in situ and carcinomas by the injection of sexually immature female rats with 1-methyl-1-nitrosoureaCarcinogenesis: Integrative Cancer Research, 1995
- Effect of carcinogen dose and age at administration on induction of mammary carcinogenesis by 1-methyl-l-nitrosoureaCarcinogenesis: Integrative Cancer Research, 1992